养正消积胶囊对肝癌经动脉化疗栓塞后生活质量的影响

目的观察养正消积胶囊对肝癌经动脉化疗栓塞(TACE)后生活质量的影响。方法将原发性肝癌患者60例随机分为对照组和治疗组,其中对照组30例,只接受TACE;治疗组30例,给予TACE+养正消积胶囊;疗程均为28 d。于术前、术后采用QOL核心量表(QLQ-C30)评估,评估其中5个功能领域、3个主要症状领域和6个单项条目。结果治疗组剔除2例,对照组剔除3例,治疗组临床获益(CB)为89.3%(25/28),对照组临床获益(CB)为92.6%(25/27),差异无统计学意义(P>0.05)。2组患者功能量表评分差异无统计学意义(P>0.05)。治疗组在疲乏、恶心呕吐、疼痛、睡眠障碍、食欲减退、腹泻等评分与治疗前比较有明显改善(P<0.05,P<0.01)。对照组仅疲乏、食欲减退较治疗前改善(P<0.05)。对照组疲乏、恶心呕吐、疼痛、睡眠障碍、食欲减退、腹泻评分分别降低了7.83%、4.01%、2.78%、7.41%、7.41%、2.74%,治疗组分别降低了11.91%、5.07%、13.99%、15.47%、15.47%、9.53%,治疗组的改善较对照组更为明显(P<0.05)。TACE术后出现骨髓抑制,对照组WBC降低多于治疗组(P<0.05),ALT、AST 2组比较差异亦有统计学意义(P<0.05)。结论养正消积胶囊能显著提高肝癌患者TACE后的生活质量。

The effect of Yangzhengxiaoji capsule on life quality after transcatheter arterial chemoembolization of HCC

Objective To observe the effect of Yangzhengxiaoji capsule on quality of life in hepatocellular carcinoma （HCC） after transcatheter arterial chemoembolization （TACE）.Methods 60 patients with primary liver cancer were random-ly divided into control group and the treatment group with 30 patients in each group , control group only accept TACE .In treat-ment group, patients received TACE ＋Yangzhengxiaoji capsule;treatment lasted 28 d.Preoperative and postoperative QOL using the core scale （ QLQ-C30） assesses five functional areas , three main symptoms areas and six individual entries .Rseults Two cases were removed in treatment group and control group excluded three cases ,treatment groups＆#39;clinic benefit （ CB） rate was 89.3%（25/28）, the control group＆#39;s CB rate was 92.6%（25/27）, the difference was not statistically significant （ P 〉0.05）.2 groups of patients function scores showed no significant difference （ P 〉0.05）.In the treatment group, fatigue, nausea, vomiting, pain, sleep disorders, loss of appetite, diarrhea score significantly improved compared with before treat-ment （ P 〈0.05, P 〈0.01）.In control group, only fatigue, loss of appetite were improvement than before treatment （ P 〈0.05）.Control group＆#39;s fatigue, nausea, vomiting,pain,sleep disorders, loss of appetite, diarrhea scores were decreased 7.83%,4.01 %2,.78%,7.41%,7.41%,2.74%,the treatment group decreased by 11.91%,5.07%, 13.99%,15.47%, 15.47%,9.53%,improvement in the treatment group was more significantly than the control group （ P 〈0.05）.TACE post-operative bone marrow suppression , WBC lower than the control group treated group （ P 〈0.05）, ALT, AST 2 group differ-ence was also statistically significant （ P 〈0.05）.Conclusion Yangzhengxiaoji capsule can significantly improve quality of life in hepatocellular carcinoma after transcatheter arterial chemoembolization .